Pierrel Logo

Pierrel

Global pharma company specializing in dental anesthetics and contract manufacturing services.

PRL | XMIL

Overview

Corporate Details

ISIN(s):
IT0005549644
LEI:
8156002BC7CB6E3BD403
Country:
Italy
Address:
STRADA STATALE APPIA 7 BIS, 46/48, 81043 CAPUA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pierrel is a global pharmaceutical company, established in 1948, specializing in the oral health sector. The company's core activities encompass the development, production, registration, and licensing of dental anesthetics and complementary medical devices. Its product portfolio features proprietary brands such as Orabloc®, Ubisestin™, Xylestesin™, and Mepivastesin™, which are distributed in global markets. Operating a production facility authorized by major regulatory bodies, including the EMA and FDA, Pierrel manufactures injectable drugs for its own brands and provides contract manufacturing services to the broader biopharmaceutical industry. The company focuses on delivering innovative solutions for dental professionals worldwide.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Pierrel and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2024-01-24 12:25
Delisting Announcement
Pierrel S.p.A.: OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA SULLE AZION…
Italian 249.0 KB
2024-01-17 19:37
Delisting Announcement
Pierrel S.p.A.: OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA SULLE AZION…
Italian 262.6 KB
2023-12-20 20:07
Post-Annual General Meeting Information
Pierrel S.p.A.: Comunicato ai sensi dell’art. 41, co. 6 RE, emesso da PRL S.p.A…
Italian 261.4 KB
2023-12-15 21:19
Delisting Announcement
Pierrel S.p.A.: Comunicato ai sensi dell’art. 36 del RE, emesso da PRL SpA
Italian 230.9 KB
2023-12-14 20:16
Pre-Annual General Meeting Information
Pierrel S.p.A.: Comunicato ai sensi degli artt. 36 e 43 del Regolamento adottat…
Italian 227.0 KB
2023-11-29 11:28
Annual / Quarterly Financial Statement
Pierrel S.p.A.: Bilancio d'esercizio al 31.12.2022
Italian 4.9 MB
2023-11-28 21:23
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 36 del RE - emesso da PRL S.p.A. …
Italian 242.8 KB
2023-11-24 23:43
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 2 RE,emesso da PRL S.p.A.…
Italian 221.8 KB
2023-11-24 19:28
M&A Activity
Pierrel S.p.A.: IL CDA DI PIERREL APPROVA IL COMUNICATO DELL’EMITTENTE IN REL. …
Italian 256.7 KB
2023-11-22 22:55
Delisting Announcement
Pierrel S.p.A.: PRL S.p.A. OFFERTA PUBBLICA DI ACQUISTO VOLONTARIA TOTALITARIA …
Italian 203.6 KB
2023-11-16 15:43
Post-Annual General Meeting Information
Pierrel S.p.A.: Informazioni essenziali Addendum al patto parasociale – 16 nove…
Italian 310.4 KB
2023-11-16 15:40
M&A Activity
Pierrel S.p.A.: Estratto Addendum al patto parasociale – 16 novembre 2023
Italian 1.2 MB
2023-11-15 11:03
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 1, del Regolamento - AVVI…
Italian 133.7 KB
2023-10-31 17:18
Regulatory News Service
Pierrel S.p.A.: Comunicato ai sensi dell’art. 38, co. 1,emesso da PRL S.p.A. e …
Italian 141.2 KB
2023-10-24 11:11
M&A Activity
Pierrel S.p.A.: Comunicato ai sensi dell’art. 102, comma 3, del D.Lgs. 24 febbr…
Italian 215.6 KB

Automate Your Workflow. Get a real-time feed of all Pierrel filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pierrel via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC

Talk to a Data Expert

Have a question? We'll get back to you promptly.